CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 22, 2021 (GLOBE NEWSWIRE)

Highlights strategic priorities to lead data-driven insights…

Read more

CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor Event

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, June 16, 2021 (GLOBE NEWSWIRE)

Further signs of recovery in the core rare disease business

Record…

Read more

CENTOGENE to Announce Q1 2021 Financial Results on June 16, 2021

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 9, 2020 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on…

Read more

CENTOGENE Announces Virtual Investor Event

New leadership team to present vision, strategy, and execution roadmap

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 7, 2020 (GLOBE…

Read more

CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia

Observational Study to Advance Genetic Understanding of FTD Being Conducted With Support From Alector

CAMBRIDGE, Mass. and ROSTOCK, Germany and…

Read more

CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 1, 2020 (GLOBE NEWSWIRE)

  • World leader and trusted partner in rare diseases releases enhanced…

Read more

CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 26, 2020 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on…

Read more

CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2020 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on…

Read more

CENTOGENE Extends Global Parkinson’s Disease Study

Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD)

Read more

New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases

CENTOGENE’s rare disease mutation database offers new features and previously unpublished variants

Read more

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads